|
63 Government plans
further review of control of entry Regulations that govern the way
in which new pharmacy contracts are awarded in England will be subject
to further Government scrutiny, health minister Andy Burnham announced
last week
PJ 2007;278:63
Full Text
63 Call for “desirable” to be restored to control of entry test wording Changing the wording of the control of entry test from “desirable” to “expedient” has made the NHS Act 2006 null and void, the National Pharmacy Association has argued
PJ 2007;278:63
Full Text
63 NPA opens debate on access to electronic
NHS care records for community pharmacists The case for community pharmacists to have “read and write” access to electronic NHS care records is set out in a National Pharmacy Association position statement this week
PJ 2007;278:63
Full Text
63 Society's national pharmacy boards elections
completed The first elections to the Royal Pharmaceutical
Society's national pharmacy boards have been completed, with polling figures
suggesting that the creation of an English Pharmacy Board has failed to attract
much interest among pharmacists
PJ 2007;278:63
Full Text
63 First independent prescriber The
first pharmacist to be awarded a practice certificate in independent prescribing
has now registered with the Royal Pharmaceutical Society and is able to practise
as an independent prescriber
PJ 2007;278:63
Full Text
64 Glasgow pharmacists to tackle
health inequalities Pharmacists in Glasgow are to play a key role in the Scottish Executive’s “Prevention 2010” initiative that aims to tackle health inequalities
PJ 2007;278:64
Full Text
64 Varencline among five drugs accepted by SMC The
smoking cessation medicine varencline is among five drugs accepted by the Scottish
Medicines Consortium for use in NHS Scotland this month
PJ 2007;278:64
Full Text
64 NHS consultation on five principles of self
care launched Consultation on five principles of
self care has been launched by NHS Skills for Health Skills for Health works
with employers to ensure that health care workers are equipped with appropriate
skills
PJ 2007;278:64
Full Text
64 Day Lewis acquires lion’s share of
Alliance Boots disposals Day Lewis pharmacy group
has agreed to purchase 31 pharmacies from Alliance Boots, representing 32 per
cent of the 96 pharmacies that the Office of Fair Trading ruled should be disposed
of following the merger of Boots The Chemists and Alliance UniChem last year
PJ 2007;278:64
Full Text
64 Patient records Guidance
on retention of patient records will not be extended to community pharmacy, according
to a Scottish Executive report
PJ 2007;278:64
Full Text
64 Generics shortage guidance Guidance
on managing shortages of generic medicines has been issued by the British Generic
Manufacturers Association and the Department of Health
PJ 2007;278:64
Full Text
64 Delivery of Pfizer products in NI UniChem
has revealed that it will not deliver Pfizer medicines in Northern Ireland from
March 2007
PJ 2007;278:64
Full Text
65 Mental health trusts need
more pharmacy input Mental health trusts should
increase the amount of clinical support provided by pharmacy staff to both wards
and community teams, according to the Healthcare Commission in a report published
last week. But there are concerns that such a development is beyond the current
capacity of most trusts
PJ 2007;278:65
Full Text
65 New opiate substitute could minimise misuse Substance
misuse clients receiving an opiate substitute can now be treated with a combination
product containing buprenorphine and naloxone
PJ 2007;278:65
Full Text
65 Lord Hunt returns Lord
Hunt of Kings Heath has returned to the Department of Health as Minister of State
for Quality
PJ 2007;278:65
Full Text
65 DVD for patients with depression Community
pharmacists in south west London are taking part in a mental health promotion
project
PJ 2007;278:65
Full Text
66 Global award for pharmacy-led
diabetes service A pharmacy-led service in Edinburgh
and the Lothians, set up to support people from ethnic minorities who are struggling
to manage their diabetes, has been recognised by the International Diabetes Federation
PJ 2007;278:66
Full Text
66 Benefits of inhaled insulin not sufficient
to outweigh disadvantages There are few situations
where the potential benefit of inhaled insulin (Exubera) outweighs its associated
safety concerns and expense, the authors of a Drug and Therapeutics Bulletinreview conclude
PJ 2007;278:66
Full Text
67 Call for new pharmacy leadership Professional
leadership in pharmacy should focus on clinical innovation in community pharmacy
practice, rather than on regulatory matters and contract terms, the Association
of the British Pharmaceutical Industry has told a Parliamentary inquiry into
the future of pharmacy. Dispensing should also become less important
PJ 2007;278:67
Full Text
67 Seven-day scripts for MDSs halted in Wales Advice
on how pharmacists should deal with GPs' withdrawal of seven-day prescriptions
has been issued by Community Pharmacy Wales
PJ 2007;278:67
Full Text
67 Welsh Assembly Government sets nine-year
cancer targets Three sets of targets for tackling
cancer between now and 2015 have been set out by the Welsh Assembly Government
PJ 2007;278:67
Full Text
R&D news
68 Potential for novel vascular targeting agent
for cancer Clinical evidence has emerged that nitric
oxide has a role in maintaining tumour blood supply and that inhibition of its
synthesis results in a sustained reduction in tumour blood volume
PJ 2007;278:68
Full Text
68 Researchers lay groundwork for large-scale
production of therapeutic proteins in eggs Hens
may in the future be used for large-scale production of therapeutic proteins,
new research published this week online suggests
PJ 2007;278:68
Full Text
68 Lapatinib shows survival benefit in breast
cancer Analysis of results from a phase III trial
of the oral dual-kinase inhibitor lapatinib (Tykerb; GlaxoSmithKline) in women
with HER2-positive advanced or metastatic breast cancer has confirmed a survival
benefit for lapatinib plus capecitabine, compared with capecitabine alone
PJ 2007;278:68
Full Text
68 Two new drugs show promising results for
AML Two drugs in development to treat acute myeloid
leukaemia (AML) have shown promising results in poor-prognosis disease in early
clinical trials
PJ 2007;278:68
Full Text
68 Pexelizumab stumbles in reperfusion trial Pexelizumab,
a humanised monoclonal antibody that binds the C5 component of complement, has
failed to improve 30-day mortality for patients with acute ST-elevation myocardial
infarction when used as an adjunct to percutaneous transluminal coronary intervention
PJ 2007;278:68
Full Text |
The
Pharmaceutical Journal